Skip to content

NuSkin Enterprises NUS Operating lease right-of-use assets amortization expense

Operating lease right-of-use assets amortization expense at other companies

USANA Health Sciences logo
USANA Health SciencesUSNA
$1.51M-20.7%

Other financials

Income statement

See full
Revenue$320.6M-12.0%
Gross profit$214.5M-13.2%
Operating income$4.0M+141%
Net income$1.8M-98.3%
EPS (diluted)$0.04-98.1%

Balance sheet

See full
Cash & equivalents$198.7M-2.5%
Total debt$303.6M-8.2%
Total equity$794.1M+5.3%
Total assets$1.4B-1.1%

Cash flow

See full
Operating cash flow-$3.9M-1,107%
CapEx$13.7M+1.0%
Free cash flow-$17.6M-33.6%

Valuation

See full
Market cap$256.35M-38.2%

Where this comes from

Reported directly by NuSkin Enterprises in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: NuSkin Enterprises’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about NuSkin Enterprises's operating lease right-of-use assets amortization expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NuSkin Enterprises's operating lease right-of-use assets amortization expense?
NuSkin Enterprises (NUS) reported operating lease right-of-use assets amortization expense of $6.45M in Q1 2026.
How has NuSkin Enterprises's operating lease right-of-use assets amortization expense changed year-over-year?
NuSkin Enterprises's operating lease right-of-use assets amortization expense increased by 0.2% year-over-year, from $6.44M to $6.45M.
What is the long-term trend for NuSkin Enterprises's operating lease right-of-use assets amortization expense?
Over 4 years (2021 to 2025), NuSkin Enterprises's operating lease right-of-use assets amortization expense has grown at a -14.3% compound annual growth rate (CAGR), from $48.7M to $26.23M.